- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Moderna to charge Govts USD 25-USD 37 per dose for Covid-19 vaccine: CEO
Bancel said that the price he quoted was a "fair price" and that the company was not interested in "maximum profit," according to the report on Sunday.
Berlin: Governments seeking to purchase Moderna's potential Covid-19 vaccine may have to shell out $25 and $37 per dose, depending on the size of the order, the company's CEO Stephane Bancel told German weekly 'Welt am Sonntag' (WamS).
Bancel said that the price he quoted was a "fair price" and that the company was not interested in "maximum profit," according to the report on Sunday.
The US pharma giant last week said that its vaccine has shown more than 94.5 percent effectiveness in preliminary data from the company's ongoing study, raising hope delivering a potent weapon to beat the pandemic.
By the end of 2020, Moderna expects to produce approximately 20 million doses of its mRNA-1273 vaccine.
The company said it remains on track to manufacture 500 million to 1 billion doses globally in 2021.
The Moderna CEO told WamS that his company was engaged in negotiations with the EU Commission for the delivery of its vaccine against Covid-19.
Saying that the talks have been "constructive", Bancel said that it was "only a matter of days" before the contract is signed.
Read also: Sputnik V to cost less than Pfizer, Moderna Covid Vaccine, claims Russia
Before Moderna, Pfizer and BioNTech said that their vaccine candidate was found to be more than 90 percent effective in preventing Covid-19.
Pfizer on Friday said that it was moving ahead with its request of asking the US regulators to grant emergency approval of its Covid-19 vaccine candidate, which has shown 95 percent efficacy in a totality of two data sets released recently.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.